Raptor Pharmaceutical to merge with TorreyPines Therapeutics

NOVATO - Raptor Pharmaceuticals Corp. has agreed to merge with TorreyPines Therapeutics Inc. (Nasdaq: TPTX), giving the Novato developer of drug-targeting platforms and mid- to late-stage clinical development candidates a listing on Nasdaq. The merged company will most likely retain the Raptor name, executive team and Novato location.

Under the terms of the agreement, approved by both boards of directors, Raptor will become a wholly owned subsidiary of TorreyPines, with Raptor stockholders receiving shares of TorreyPines common stock and holding approximately 95 percent of the combined company. In addition, at closing TorreyPines will implement a reverse stock split - the size to be determined at closing - to ensure compliance with Nasdaq listing requirements.

The combined company will continue to address unmet medical needs and underserved patient population by developing new treatments or improving existing therapeutic compounds. Raptor currently has product candidates in clinical development to treat nephropathy cystinosis, non-alcoholic steatohepatitis, Huntington's Disease and aldehyde dehydrogenase deficiency.

Christopher Starr, Ph.D., will remain as CEO and Ted Daley as president of the merged company.

In June of 2008 Raptor closed a $10 million private placement of its stock, netting the company $9.3 million, which was expected to take Raptor to the second quarter of 2009. The company has been seeking development partners here and abroad, according to Mr. Daley in a previous interview.

© The North Bay Business Journal  |  Terms of Service |  Privacy Policy |  Jobs With Us |  RSS |  Advertising |  Sonoma Media Investments
Switch to our Mobile View